Axon Neuroscience initiates Phase II trial of tau vaccine AADvac1 to treat Alzheimer’s disease

Slovakia-based biotech company Axon Neuroscience has started the Adamant Phase II trial by administering the first patient with its active tau vaccine, AADvac1, to treat Alzheimer’s disease.

Free Case Study

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges

By Suvoda

By clicking the Download Free Case Study button, you accept the terms and conditions and acknowledge that your data will be used as described in the Suvoda privacy policy

By downloading this Case Study, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The randomised, placebo-controlled, parallel group, double-blinded, multi-centre Adamant Phase II trial will be held for a period of 24 months.

It plans to enrol 185 patients and will be conducted across several countries in Europe.

The trial is primarily focused on assessing the safety and immunogenicity aspect of AADvac1 to treat mild Alzheimer’s.

The trial’s secondary objective is to measure the efficacy of the vaccine in diminishing or stopping the effect of the disease in the patients during the 24 months.

"AADvac1 is an active tau vaccine developed to act as a disease-modifying treatment for Alzheimer’s and other tauopathies."

AXON Neuroscience CEO Roman Sivak said: "We are grateful for all the efforts of the entire team, investigators, and partners, who helped us to move AADvac1 into the phase II study, which is a historical milestone for Alzheimer’s research and clinical development."

AADvac1 is an active tau vaccine developed to act as a disease-modifying treatment for Alzheimer’s and other tauopathies.

It draws out antibodies against the pathological tau protein, which is recognized as the primary cause of neurofibrillary pathology in Alzheimer’s disease.

The tau protein will be blocked by these antibodies from pathological interactions which will result to the removal of tau pathology, thereby diminishing or stopping the progress of Alzheimer’s disease.

Image: Illustration of changes in tau protein causing Alzheimer’s disease. Photo: courtesy of Adear via Wikipedia.